The clinical impact of MTHFR polymorphism on the vascular complications of sickle cell disease

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 10, 2006, Pages 1291-1295

  Moreira Neto, F ^a   Lourenco D M ^a   Noguti, M A E ^a   Morelli, V M ^a   Gil, I C P ^a   Beltrao A C S ^a   Figueiredo, M S ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Inherited hypercoagulation states; MTHFR polymorphism; SC hemoglobinopathy; Sickle cell disease; Sickle hemoglobinopathies

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BETA GLOBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; ENDONUCLEASE; HEMOGLOBIN F; PROTHROMBIN;

ADOLESCENT; ADULT; AGED; ALLELE; ALPHA THALASSEMIA; ARTICLE; AVASCULAR NECROSIS; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HEMOGLOBIN SC DISEASE; HEMOGLOBINOPATHY; HEREDITY; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; RETINOPATHY; RISK FACTOR; SICKLE CELL ANEMIA; STROKE; THORAX OUTLET SYNDROME; VASCULAR DISEASE;

EID: 33847643697     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006001000004     Document Type: Article

References (33)

1. Lyra IM, Goncalves MS, Braga JA, Gesteira MF, Carvalho MH, Saad ST, et al. Clinical, hematological, and molecular characterization of sickle cell anemia pediatric patients from two different cities in Brazil. Cad Saude Publica 2005; 21: 1287-1290.
2. Steinberg MH, Rosenstock W, Coleman MB, Adams JG, Platica O, Cedeno M, et al. Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood 1984; 63: 1353-1360.
3. s Gene cluster haplotypes in sickle cell anemia. Clinical and hematologic features. Hematol Oncol Clin North Am 1991; 5: 475-493.
4. Rieder RF, Safaya S, Gillette P, Fryd S, Hsu H, Adams JG III, et al. Effect of beta-globin gene cluster haplotype on the hematological and clinical features of sickle cell anemia. Am J Hematol 1991; 36: 184-189.
5. Figueiredo MS, Kerbauy J, Goncalves MS, Arruda VR, Saad ST, Sonati MF, et al. Effect of alpha-thalassemia and beta-globin gene cluster haplotypes on the hematological and clinical features of sickle-cell anemia in Brazil. Am J Hematol 1996; 53: 72-76.
6. Lourenço D, Sampaio MU, Kerbauy J, Sampaio CA. Estimation of plasma kallikrein in sickle-cell anemia, and its relation to the coagulation and fibrinolytic systems. Adv Exp Med Biol 1989; 247B: 553-557.
7. Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 1994; 71: 169-172.
8. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-4223.
9. Bayazit AK, Kilinc Y. Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state. Pediatr Int 2001; 43: 592-596.
10. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001; 98: 3228-3233.
11. Hebbel RP. Thrombogenesis or thrombogenic risk? J Lab Clin Med 2001; 137: 381-382.
12. Arruda VR, Annichino-Bizzacchi JM, Costa FF, Reitsma PH. Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol 1995; 49: 242-243.
13. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
14. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
15. Nagel RL. Severity, pathobiology, epistatic effects, and genetic markers in sickle cell anemia. Semin Hematol 1991; 28: 180-201.
16. Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001; 97: 1584-1589.
17. Cumming AM, Olujohungbe A, Keeney S, Singh H, Hay CR, Serjeant GR. The methylenetetrahydrofolate reductase gene C677T polymorphism in patients with homozygous sickle cell disease and stroke. Br J Haematol 1999; 107: 569-571.
18. Balasa VV, Kalinyak KA, Bean JA, Stroop D, Gruppo RA. Hyperhomocysteinemia is associated with low plasma pyridoxine levels in children with sickle cell disease. J Pediatr Hematol Oncol 2002; 24: 374-379.
19. Zimmerman SA, Ware RE. Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol 1998; 59: 267-272.
20. Romana M, Muralitharan S, Ramasawmy R, Nagel RL, Krishnamoorthy R. Thrombosis-associated gene variants in sickle cell anemia. Thromb Haemost 2002; 87: 356-358.
21. Koch HG, Nabel P, Junker R, Auberger K, Schobess R, Homberger A, et al. The 677T genotype of the common MTHFR thermolabile variant and fasting homocysteine in childhood venous thrombosis. Eur J Pediatr 1999; 158 (Suppl 3): S113-S116.
22. Brown K, Luddington R, Baglin T. Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol 1998; 103: 42-44.
23. Alhenc-Gelas M, Arnaud E, Nicaud V, Aubry ML, Fiessinger JN, Aiach M, et al. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81: 506-510.
24. Kluijtmans LA, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998; 79: 254-258.
25. Margaglione M, D'Andrea G, d'Addedda M, Giuliani N, Cappucci G, Iannaccone L, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998; 79: 907-911.
26. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-518.
27. Morelli VM, Lourenço DM, D'Almeida V, Franco RF, Miranda F, Zago MA, et al. Hyperhomocysteinemia increases the risk of venous thrombosis independent of the C677T mutation of the methylenetetrahydrofolate reductase gene in selected Brazilian patients. Blood Coagul Fibrinolysis 2002; 13: 271-275.
28. Franco RF, Reitsma PH, Lourenço D, Maffei FH, Morelli V, Tavella MH, et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost 1999; 81: 676-679.
29. Andrade FL, Annichino-Bizzacchi JM, Saad ST, Costa FF, Arruda VR. Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahydrofolate reductase among patients with sickle cell disease in Brazil. Am J Hematol 1998; 59: 46-50.
30. Kutlar A, Kutlar F, Turker I, Tural C. The methylene tetrahydrofolate reductase (C677T) mutation as a potential risk factor for avascular necrosis in sickle cell disease. Hemoglobin 2001; 25: 213-217.
31. Zalavras CG, Malizos KN, Dokou E, Vartholomatos G. The 677C←T mutation of the methylene-tetrahydrofolate reductase gene in the pathogenesis of osteonecrosis of the femoral head. Haematologica 2002; 87: 111-112.
32. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
33. Houston PE, Rana S, Sekhsaria S, Perlin E, Kim KS, Castro OL. Homocysteine in sickle cell disease: relationship to stroke. Am J Med 1997; 103: 192-196.